Recently, Sakaguchi et al. conducted a multicenter, single-arm, phase II clinical trial of first-line eribulin and trastuzumab in 28 Japanese women with naïve progressive or recurrent HER2-positive breast cancer [35]. The gene discussed is ERBB2; the disease is breast cancer.